本案例依原書 Table 11.4 完整整理。
比較 Resource-abundant 與 Resource-constrained Pharmaceutical Organization 如何部署 RAG。
原書主張 RAG 導入不能 one-size-fits-all；資源充足者可 Full-scale Integration，資源有限者可用 Open-source／Hybrid Infrastructure 與 Phased Adoption。
| Implementation aspect | Resource-abundant | Resource-constrained | Recommended focus |
|---|---|---|---|
| Infrastructure setup | Dedicated AI/ML servers；enterprise cloud（AWS／Azure）；ERP／SCM full integration | Hybrid／open-source cloud（LangChain／LlamaIndex）；existing IT hardware | Open-source first；API compatibility for scaling |
| Human capital | Specialized AI／data science team（5–10 experts） | Cross-trained IT staff＋short-term AI consultancy | Modular training；data literacy |
| Data readiness | Centralized data lake＋automated governance／lineage | Structured DB＋standardized format＋periodic validation | 先做 data quality／consistency |
| Adoption strategy | Full-scale end-to-end AI deployment | Phased，先 high-impact／low-complexity | Supplier risk、demand forecasting、compliance retrieval |
| Regulatory alignment | Automated compliance verification＋continuous monitoring | Manual process augmented by AI validation | Early alignment with CDSCO、HIPAA、GDPR |
| Performance measurement | Real-time KPI dashboards＋predictive analytics | Periodic review：accuracy、response time、ROI | 用 Pilot Result 決定 scaling／investment |
| Expected outcomes | 40–60% improvement in process efficiency；enhanced resilience | 20–35% reduction in operational costs through automation | Build sustainable、scalable AI capability |
先做 Resource Profile，再選 Deployment Pattern；Expected Outcome 要與 Actual Pilot KPI 分欄，禁止混合。
Table 11.4 提供的 40–60% 與 20–35% 是框架中的 Expected Outcomes；原書沒有說這兩個區間來自 XYZ Pharma Table 11.3 的實測。
資源不足不代表不能導入；原書建議從 High-impact／Low-complexity Use Case 與 Open-source Tool 開始，再以 Pilot Evidence 決定擴大。
請依 Table 11.4 判斷一間 resource-constrained pharma firm 的最低可行 RAG roadmap，並將 expected outcomes 與 measured outcomes 分開呈現。